REGULATORYSTORY 556· AUGUST 4, 2026

Palvella Therapeutics files first NDA module for rare lymphatic disease drug, holds $250.6 million in cash

A drug application that lets the FDA begin reviewing completed portions before the full package arrives has reached federal regulators for a treatment targeting a serious, rare condition with no approved therapies in the United States…

NDNewsDialy Desk3 MIN READPVLA

SOURCE

sec.gov

← PREVIOUS STORY 555Trump warns Iran talks are a 'last chance' as Bessent says Hormuz deal is in sight NEXT STORY 557 →BP to sell $4 billion US biogas business as profits more than double

Keep reading

More from the desk.

01REGULATORY

Cardinal Infrastructure's contracting subsidiary adds $250 million in new borrowing capacity

A credit agreement amendment, a formal revision to an existing loan rather than a new deal, closed September 10, 2026, opening up to $250 million in new borrowing capacity for the contracting subsidiary of Cardinal Infrastructure Group…

regulatory2 MIN

03REGULATORY

U.S. appeals courts split on prediction market contracts, Supreme Court fight likely

Two federal appeals courts have now reached opposite conclusions on whether sports-related event contracts are swaps, a class of regulated financial instrument under federal law. The Ninth Circuit Court of Appeals ruled that those…

regulatory2 MIN

04REGULATORY

NFL's top preseason pick opens 2026 with a loss as full-season projections favor the Bengals

A preseason favorite, in football terms the team most analysts expect to win the championship before a single game is played, rarely keeps that label undisturbed. The Los Angeles Rams held it going into 2026. They lost the opener to the…

regulatory2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk